| Year |
Citation |
Score |
| 2013 |
Benucci M, Stam WB, Gilloteau I, Sennfält K, Leclerc A, Maetzel A, Lucioni C. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Clinical and Experimental Rheumatology. 31: 575-83. PMID 23711100 |
0.371 |
|
| 2012 |
Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L. The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis: a knowledge translation randomized controlled trial: part II: clinical outcomes. Bmc Public Health. 12: 1073. PMID 23234575 DOI: 10.1186/1471-2458-12-1073 |
0.301 |
|
| 2012 |
Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L. The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs). Bmc Public Health. 12: 871. PMID 23061875 DOI: 10.1186/1471-2458-12-871 |
0.318 |
|
| 2009 |
Boonen A, Maetzel A, Drummond M, Suarez-Almazor M, Harrison M, Welch V, Tugwell PS. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. The Journal of Rheumatology. 36: 2045-9. PMID 19738211 DOI: 10.3899/Jrheum.090355 |
0.32 |
|
| 2008 |
Sander B, Elliot-Gibson V, Beaton DE, Bogoch ER, Maetzel A. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs. The Journal of Bone and Joint Surgery. American Volume. 90: 1197-205. PMID 18519311 DOI: 10.2106/Jbjs.G.00980 |
0.507 |
|
| 2008 |
Clark P, Carlos F, Barrera C, Guzman J, Maetzel A, Lavielle P, Ramirez E, Robinson V, Rodriguez-Cabrera R, Tamayo J, Tugwell P. Direct costs of osteoporosis and hip fracture: An analysis for the Mexican healthcare system Osteoporosis International. 19: 269-276. PMID 18060586 DOI: 10.1007/S00198-007-0496-8 |
0.338 |
|
| 2007 |
Osiri M, Kamolratanakul P, Maetzel A, Tugwell P. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. Rheumatology International. 27: 1063-9. PMID 17440729 DOI: 10.1007/S00296-007-0342-5 |
0.466 |
|
| 2007 |
Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. The Journal of Rheumatology. 34: 57-63. PMID 17183621 |
0.384 |
|
| 2006 |
Li LC, Maetzel A, Davis AM, Lineker SC, Bombardier C, Coyte PC. Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: a cost-effectiveness analysis. Arthritis and Rheumatism. 55: 402-10. PMID 16739183 DOI: 10.1002/Art.21989 |
0.579 |
|
| 2005 |
Maetzel A. Cost-effectiveness analysis: out of touch with clinical reality? Arthritis and Rheumatism. 53: 3-4. PMID 15696549 DOI: 10.1002/Art.20906 |
0.337 |
|
| 2004 |
Li LC, Maetzel A, Pencharz JN, Maguire L, Bombardier C. Use of mainstream nonpharmacologic treatment by patients with arthritis. Arthritis and Rheumatism. 51: 203-9. PMID 15077260 DOI: 10.1002/Art.20244 |
0.554 |
|
| 2004 |
Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Annals of the Rheumatic Diseases. 63: 395-401. PMID 15020333 DOI: 10.1136/Ard.2003.006031 |
0.548 |
|
| 2003 |
Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and Rheumatism. 49: 283-92. PMID 12794781 DOI: 10.1002/Art.11121 |
0.442 |
|
| 2003 |
Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a consensus-based reference case Journal of Rheumatology. 30: 891-896. PMID 12672224 |
0.326 |
|
| 2003 |
Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. The Journal of Rheumatology. 30: 886-90. PMID 12672223 |
0.33 |
|
| 2002 |
Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis and Rheumatism. 47: 655-61. PMID 12522841 DOI: 10.1002/Art.10793 |
0.567 |
|
| 2002 |
Maetzel A, Li L. The economic burden of low back pain: a review of studies published between 1996 and 2001. Best Practice & Research. Clinical Rheumatology. 16: 23-30. PMID 11987929 DOI: 10.1053/Berh.2001.0204 |
0.396 |
|
| 2002 |
Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Pharmacoeconomics. 20: 61-70. PMID 11817993 DOI: 10.2165/00019053-200220010-00006 |
0.583 |
|
| 2001 |
Gabriel S, Drummond M, Suarez-Almazor ME, Ruff B, Guillemin F, Bombardier C, Boers M, Maetzel A, Ruof J, Cranney A, Marentette M, Tugwell P. OMERACT 5 Economics Working Group: summary, recommendations, and research agenda. The Journal of Rheumatology. 28: 670-3. PMID 11296980 |
0.369 |
|
| 2000 |
Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford, England). 39: 975-81. PMID 10986302 DOI: 10.1093/Rheumatology/39.9.975 |
0.568 |
|
| 2000 |
Maetzel A, Johnson SH, Woodbury M, Bombardier C. Use of grade membership analysis to profile the practice styles of individual physicians in the management of acute low back pain. Journal of Clinical Epidemiology. 53: 195-205. PMID 10729692 DOI: 10.1016/S0895-4356(99)00120-1 |
0.459 |
|
| 2000 |
Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A, Tindall E, Offenberg H, Poiley J, Rutstein J, Dietz F, Brodsky A, Harris R, et al. Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial Arthritis and Rheumatism. 43: 506-514. PMID 10728742 DOI: 10.1002/1529-0131(200003)43:3<506::Aid-Anr5>3.0.Co;2-U |
0.505 |
|
| 1999 |
Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Annals of the Rheumatic Diseases. 58: I82-5. PMID 10577979 |
0.471 |
|
| 1999 |
Maetzel A, Bombardier C. Give observational studies a chance: better observational studies make better economic evaluations. The Journal of Rheumatology. 26: 2298-9. PMID 10555880 |
0.408 |
|
| 1999 |
Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism. 42: 1870-8. PMID 10513801 DOI: 10.1002/1529-0131(199909)42:9<1870::Aid-Anr11>3.0.Co;2-D |
0.55 |
|
| 1998 |
Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. The Journal of Rheumatology. 25: 2331-8. PMID 9858426 |
0.508 |
|
| 1998 |
Maetzel A, Ferraz MB, Bombardier C. A review of cost-effectiveness analyses in rheumatology and related disciplines. Current Opinion in Rheumatology. 10: 136-40. PMID 9567209 DOI: 10.1097/00002281-199803000-00009 |
0.554 |
|
| 1998 |
Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism. 41: 16-25. PMID 9433865 DOI: 10.1002/1529-0131(199801)41:1<16::Aid-Art3>3.0.Co;2-4 |
0.539 |
|
| 1997 |
Ferraz MB, Maetzel A, Bombardier C. A summary of economic evaluations published in the field of rheumatology and related disciplines. Arthritis and Rheumatism. 40: 1587-93. PMID 9324012 DOI: 10.1002/Art.1780400907 |
0.457 |
|
| 1997 |
Maetzel A, Mäkelä M, Hawker G, Bombardier C. Osteoarthritis of the hip and knee and mechanical occupational exposure--a systematic overview of the evidence. The Journal of Rheumatology. 24: 1599-607. PMID 9263158 |
0.383 |
|
| 1996 |
Ferraz MB, Maetzel A, Bombardier C. Critical appraisal of economic evaluations published in the field of rheumatology and related disciplines Journal of Clinical Epidemiology. 49: S18. DOI: 10.1016/0895-4356(96)89221-3 |
0.405 |
|
| Show low-probability matches. |